1. Korea Centers for Disease Control and Prevention. The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) 2009-Health Examination. Korea Centers for Disease Control and Prevention;2010.
2. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4:74–80. PMID:
22489259.
Article
3. Hussain M, Lok AS. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat. 1999; 6:183–194. PMID:
10607230.
Article
4. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006; 44:593–606. PMID:
16455151.
Article
5. Yim HJ. Hepatitis B virus genetic diversity and mutant. Korean J Hepatol. 2008; 14:446–464. PMID:
19119240.
Article
6. Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol. 2005; 11:867–870. PMID:
15682483.
Article
7. Zhao J, Guo Y, Yan Z, Liang P, Zhang J, Liu Y. The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis. 2012; 44:44–47. PMID:
21851334.
Article
8. Tan YW, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, et al. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis. 2012; 16:250–255. PMID:
22729192.
Article
9. Orlando R, Tosone G, Portella G, Veropalumbo E, D'Onofrio M, Piazza M. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report. Infection. 2008; 36:472–474. PMID:
17962902.
Article
10. Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther. 2009; 31:360–366. PMID:
19302908.
Article
11. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol. 2006; 78(S1):S52–S55. PMID:
16622878.
Article
12. Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, et al. The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection. Korean J Hepatol. 2008; 14:503–512. PMID:
19119245.
Article
13. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther. 2007; 12(S3):H15–H23. PMID:
18284179.
14. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012; 18:109–162. PMID:
22893865.
15. Yuen MF, Ng IO, Fan ST, Yuan HJ, Wong DK, Yuen JC, et al. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol. 2004; 99:2032–2037. PMID:
15447768.
Article
16. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003; 37:1309–1319. PMID:
12774009.
Article
17. Alagiozian-Angelova V, Alagiozian D, Antonov K, Krustev Z. Clinical significance of serum HBeAg and HBV-DNA-specific values of virus replication in chronic hepatitis-B virus infection. Folia Med (Plovdiv). 1998; 40:34–41. PMID:
10371797.
18. Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, et al. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol. 2007; 79:1664–1670. PMID:
17854034.
Article
19. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107:449–455. PMID:
11181644.
Article